Written comments and recommendations concerning the proposed information collection should be sent by August 5, 2005, to: SAMHSA Desk Officer, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503; due to potential delays in OMB’s receipt and processing of mail sent through the U.S. Postal Service, respondents are encouraged to submit comments by fax to: 202–395–6974.

Dated: June 29, 2005.

Patricia S. Bransford,
Acting Executive Officer, SAMHSA.

Federal Register

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) notifies Federal agencies of the laboratories currently certified to meet the standards of Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on April 13, 2004 (69 FR 19644). A notice listing all currently certified laboratories is published in the Federal Register during the first week of each month. If any laboratory’s certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at http://workplace.samhsa.gov and http://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, SAMHSA/CSAP, Room 2–1035, 1 Choke Cherry Road, Rockville, Maryland 20857; 240–276–2600 (voice), 240–276–2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100–71. Subpart C of the Mandatory Guidelines, “Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies,” sets strict standards that laboratories must meet in order to conduct drug and specimen validity tests on urine specimens for Federal agencies. To become certified, an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A laboratory must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Mandatory Guidelines dated April 13, 2004 (69 FR 19644), the following laboratories meet the minimum standards to conduct drug and specimen validity tests on urine specimens:


Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229–671–2281.

DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 206–386–2661/800–898–0180, (Formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.).

DrugScan, Inc., P.O. Box 2969, 1119 Mears Road, Warminster, PA 18074, 215–674–9310.


<table>
<thead>
<tr>
<th>Form</th>
<th>Number of respondents</th>
<th>Responses per respondents</th>
<th>Hours per responses</th>
<th>Total hour burden</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual Crisis Counseling Services Encounter Log</td>
<td>7,500</td>
<td>1</td>
<td>0.03</td>
<td>225</td>
</tr>
<tr>
<td>Group Encounter Log Form</td>
<td>4,000</td>
<td>1</td>
<td>0.03</td>
<td>120</td>
</tr>
<tr>
<td>Weekly Tally Sheet</td>
<td>4,000</td>
<td>1</td>
<td>0.08</td>
<td>320</td>
</tr>
<tr>
<td>Assessment &amp; Referral Tool</td>
<td>100</td>
<td>1</td>
<td>0.08</td>
<td>8</td>
</tr>
<tr>
<td>Participant Feedback</td>
<td>1,000</td>
<td>1</td>
<td>0.06</td>
<td>60</td>
</tr>
<tr>
<td>CCP Service Provider Feedback</td>
<td>100</td>
<td>1</td>
<td>0.08</td>
<td>8</td>
</tr>
<tr>
<td>Total</td>
<td>16,700</td>
<td></td>
<td></td>
<td>741</td>
</tr>
</tbody>
</table>

ESTIMATES OF ANNUALIZED HOUR BURDEN
General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 606–267–6225.


LabOne, Inc., 10101 Renner Blvd., Lenexa, KS 66219, 913–888–3927/800–873–8845, (Formerly: Center for Laboratory Services, a Division of LabOne, Inc.).

Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713–856–8288/800–800–2387.

Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908–526–2400/800–437–4986, (Formerly: Roche Biomedical Laboratories, Inc.).


Laboratory Corporation of America Holdings, 10788 Roselle St., San Diego, CA 92121, 800–882–7272, (Formerly: Poisonlab, Inc.).

Laboratory Corporation of America Holdings, 1120 Main Street, Southhaven, MS 38671, 666–827–8042/800–233–6339, (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center).

Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449, 715–389–3734/800–331–3734.

MAXXAM Analytics Inc.*, 6740 Campbello Road, Mississauga, ON, Canada L5N 2L8, 905–817–5700, (Formerly: NOVAMANN (Ontario), Inc.).


MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503–413–5295/800–950–5295.

Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612–725–2088.


Northwest Toxicology, a LabOne Company, 2282 South Presidents Drive, Suite C, West Valley City, UT 84120, 801–606–6301/800–322–3361, (Formerly: LabOne, Inc., dba Northwest Toxicology; NWT Drug Testing, Northwest Toxicology, Inc.; Northwest Drug Testing, a division of NWT Inc.).

One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, 897–437–3774, (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory).

Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave., Eugene, OR 97440–0972, 541–687–2314.

Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, 800–328–6942, (Formerly: Centinela Hospital Airport Toxicology Laboratory).

Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204, 509–755–8991/800–541–7897X.


Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 30340, 770–452–1500/800–729–6432, (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bi-Science Laboratories).

Quest Diagnostics Incorporated, 4770 Regent Blvd., Irvine, CA 92663, 800–824–6152, (Moved from the Dallas location on 03/31/01; Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bi-Science Laboratories).


Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403, 610–631–4600/877–642–2216, (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bi-Science Laboratories).


South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 574–234–4176x276.


Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus, 1210 W. Saginaw, Lansing, MI 48915, 517–364–7400, (Formerly: St. Lawrence Hospital & Healthcare System).

St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101, 405–272–7052.

Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 65203, 573–882–1273.


U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George G. Meade, MD 20755–5235, 301–677–7085.

*The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 13, 2004 (69 FR 6544). After receiving DOT certification, the laboratory will be included in the monthly list of HHS-certified laboratories and participate in...
DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4837–D–58]

Revocation and Redelegation of Fair Housing Act Complaint Processing Authority

AGENCY: Office of the Assistant Secretary for Fair Housing and Equal Opportunity, HUD.

ACTION: Notice of revocation and redelegation of authority.

SUMMARY: The General Deputy Assistant Secretary for Fair Housing and Equal Opportunity (FHEO) revokes the prior redelegation of his authority for Fair Housing Act complaint processing, made on August 4, 2003 (68 FR 45846), and redelegates complaint processing authority to FHEO field and headquarters staff.

EFFECTIVE DATE: June 23, 2005.

FOR FURTHER INFORMATION CONTACT: Karen A. Newton, Deputy Assistant Secretary for Operations and Management, Office of Fair Housing and Equal Opportunity, Department of Housing and Urban Development, 451 Seventh Street SW., Room 5128, Washington, DC 20410–0001, telephone (202) 708–0768. (This is not a toll-free number.) Hearing- and speech-impaired individuals may access this number through TTY by calling the toll-free Federal Information Relay Service at (800) 877–8339.

SUPPLEMENTARY INFORMATION: In a March 30, 1989, notice (54 FR 13121), the Secretary of HUD delegated the authority to enforce the Fair Housing Act to the Assistant Secretary for FHEO and the General Counsel. On August 4, 2003 (68 FR 45846), the Assistant Secretary for FHEO revoked all prior redelegations of authority for complaint processing under the Fair Housing Act (42 U.S.C. 3601 et seq.) and redelegated that authority to the General Deputy Assistant Secretary for Fair Housing and Equal Opportunity. The General Deputy Assistant Secretary then further redelegated that complaint processing authority to field and headquarters staff.

After the August 4, 2003 redelegations, the FHEO Hub Directors’ titles were changed to FHEO Region Directors. Additionally the Young Implementation Office closed and, consequently, there is no longer a need for delegations of authority to the Young Implementation Office. Additionally, effective January 23, 2005, FHEO created an Office of Systemic Investigations.

The Assistant Secretary’s August 4, 2003 redelegation of authority for complaint processing under the Fair Housing Act to the General Deputy Assistant Secretary for FHEO remains intact. However, the General Deputy Assistant Secretary revokes the redelegations of Fair Housing Act complaint processing authority issued by him on August 4, 2003, and redelegates that authority as provided in this notice.

Section A. Authority Redelegated

The General Deputy Assistant Secretary for FHEO retains and redelegates the Fair Housing Act complaint processing authority under 24 CFR part 103 to the Deputy Assistant Secretary for Enforcement and Programs.

The Deputy Assistant Secretary for Enforcement and Programs retains and further redelegates the Fair Housing Act complaint processing under 24 CFR part 103, subparts A, B, C, D (with the exception of the filing of a Secretary-initiated complaint under 24 CFR 103.204(a)), E, and F, to the FHEO Region Directors, the FHEO Director of the Office of Enforcement, and the FHEO Director of the Office of Systemic Investigations.

The Deputy Assistant Secretary for Enforcement and Programs for FHEO retains and further redelegates the authority under 24 CFR 103.510(a) and (d) of 24 CFR subpart H to the FHEO Region Directors, the Director of the Office of Enforcement, and the Director of the Office of Systemic Investigations, with the exception of pattern and practice referrals to the Attorney General, which are redelegated only to the Director of the Office of Enforcement, and the Director of the Office of Systemic Investigations.

The Deputy Assistant Secretary for Enforcement and Programs for FHEO retains and further redelegates the authority to reconsider no cause determinations (issued pursuant to 24 CFR 103.400(a)(2)(ii)) to the Director of the Office of Enforcement.

Section B. Authority To Further Redelegate

The Deputy Assistant Secretary for Enforcement and Programs may redelegate the authorities provided in Section A of this notice. The Director of the Office of Enforcement, the FHEO Region Directors, and the Director of the Office of Systemic Investigations may not redelegate the authorities provided in Section A of this notice.

Section C. Authority Revoked

The August 4, 2003, redelegations of the General Deputy Assistant Secretary’s authority (68 FR 45846) is revoked.

Authority: Section 7(d) of the Department of Housing and Urban Development Act (42 U.S.C. 3535(d)).

Dated: June 23, 2005.

Floyd O. May,
General Deputy, Assistant Secretary for Fair Housing and Equal Opportunity.